SterileAtlas Marketplaces

DiscoveryAcademic Preclinical Labs Process Dev (PDO)CDMOs

ClinicalCROs Clinical Sites Ethics / IRB Central Labs

QualityPharmacovigilance Regulatory Engineering Consultants

SupplySuppliers Equipment Packaging

DistributionLogistics Distribution Specialty Pharmacy

AccessPayers PBM

CapitalInvestors IP & Legal

SterileAtlasIntelligence Mission Control

Loading…

SterileAtlas

One marketplace for the entire drug lifecycle — global sterile pharmaceutical & biotech manufacturing intelligence.

Marketplaces

All 22 marketplaces
CDMOs
CROs
Clinical trial sites
Consultants

Opportunities

Projects, jobs & leads
Open projects
Jobs
Consulting leads

Platform

Pricing
About us
List your company
Mission Control

© 2026 SterileAtlas · Capability scores are deterministic, rules-based — not AI.

About us Terms Usage Policy Disclosures Compliance Community guidelines Privacy Cookies Refunds DPA Trust & security

Data shown across the platform is illustrative and unverified — not for vendor qualification or regulatory use.

Market Access & Reimbursement

Payers

Coverage, formulary & market access

5

payers listed

Health plans, coverage, formulary and market-access partners — the reimbursement path your launch depends on.

SearchFaceted, over real records CompareSide-by-side scorecards Post an RFxGet qualified responses CollaborateRun it in a shared room AI assistantYour organisation, this market

Scores are deterministic, rules-based — not AI.

MarketplacesPayers

5 payers

Sort

Coverage reach Formulary strength Reimbursement capability Value contracting Access efficiency Compliance maturity Name (A–Z)

Therapeutic focus

Cardiometabolic5 Oncology5 Immunology3 Rare disease3 Infectious disease2 Primary care2 Specialty2 Cell & gene therapy1

Contracting

Value-based contracting Risk sharing Outcomes-based Budget-impact modeling Real-world evidence

Access management

Prior authorization Step therapy Coverage determination Appeals management Digital portal

Coverage focus

Oncology Cell & gene therapy Rare disease Biologics Vaccines Specialty drug

Status

Verified Accepting partners

Formulary structure

Managed7 Open6 Tiered5 Closed1

Ownership

Public9 Government6 Mutual3 Private1

Formulary win rate

Any win rate ≥ 50% formulary wins ≥ 55% formulary wins ≥ 60% formulary wins ≥ 65% formulary wins

Approval rate

Any approval rate ≥ 82% approval ≥ 85% approval ≥ 88% approval

Network size

Any network size ≥ 250k providers ≥ 500k providers ≥ 1M providers

Appeal success

Any appeal success ≥ 30% appeals upheld ≥ 35% appeals upheld ≥ 40% appeals upheld

Country

China France Germany Japan Spain USA United Kingdom

Showing 5 of 5Clear filters China

NHSA

National Healthcare Security Administration

Government Program · Beijing, China

43reach

OncologyRare diseaseCell & gene therapyImmunology

Value-basedSpecialtyNRDL (China)NMPAHTA

FORM 75REIMB 792 locations

Accepting partnersRegional

Ping An Health Insurance

Commercial Insurer · Shenzhen, China

36reach

OncologyImmunologyCardiometabolicRare disease

Value-basedSpecialtyNRDL (China)NMPAHTA

FORM 66REIMB 792 locations

Accepting partnersFocused

UEBMI

Urban Employee Basic Medical Insurance

Government Program · Beijing, China

33reach

OncologyCardiometabolicImmunologyRare disease

Value-basedSpecialtyNRDL (China)NMPA

FORM 66REIMB 791 locations

Accepting partnersFocused

CLI

China Life Insurance

Commercial Insurer · Beijing, China

29reach

CardiometabolicOncologyPrimary careSpecialty

SpecialtyNRDL (China)NMPA

FORM 43REIMB 791 locations

Accepting partnersFocused

URRBMI

Urban-Rural Resident Basic Medical Insurance

Government Program · Beijing, China

29reach

Primary careCardiometabolicInfectious diseaseOncology

SpecialtyNRDL (China)NMPA

FORM 43REIMB 721 locations

Accepting partnersFocused